Parkinson Pipeline Project

The Pipeline Project Needs Your Help

What's New...

Read the Testimony of Amy Comstock Rick, CEO- Parkinson’s Action Network
For the U.S. House of Representatives Committee on Small Business Subcommittee on Investigations and Oversight. Hearing on "SBIR: Advancing Medical Breakthroughs"

Tom Isaacs, Parkinson’s
advocate from the UK is
author of a new book -
Shake Well Before Use
- the story of his inspirational
walk around the coastline of
Britain to raise money for PD
research and coping with
Parkinson's from the age of 27.

Forbes Magazine
Former Intel chief talks to Forbes about his battle with Parkinson's and funding the search for a cure

Article - Andy's Grove's
Last Stand

Video - Andy Grove on Parkinson's Disease

Video - Michael J Fox's Race Against the Clock

University of Rochester
to study ethics of sham
surgery Click here to read about the study

READ Andy Grove's speech to the Society for Neuroscience in its entirety

Click Here to view selected
video clips from
Andy Grove's speech at the
Society for Neuroscience,
November 4, 2007

See OP ED Profit Over
Common Sense

Updated GDNF Information

Survey on SHAM SURGERY in Parkinson’s clinical research.
The Results of
the recent poll.

Questions and Answers About "Off-Label" Use of Prescription Drugs

The Prescription Drug User Fee Act of 2007 (PDUFA)

The Parkinson Pipeline
Project is supported by
the Parkinson's Disease Foundation (PDF),
a 501(c)3 Corporation headquartered in New York City.

Tax deductible donations to the Parkinson Pipeline Project, made through this website to Donate.net, go
to the PDF designated for use by the Parkinson Pipeline Project.

What is the Pipeline Project?

The Parkinson Pipeline Project is a grassroots group of advocates whose goal is to provide the patient perspective in the treatment development process. Through education, consultation, and participation with all stakeholders - including industry and the FDA - the Parkinson Pipeline Project hopes to increase clinical trial participation and accelerate approved treatment options. New PD treatments are followed from pre-clinical development to approval in the Pd Pipeline Database found on our website. More info...

"The missing ingredient in the development of new therapies is the voice of the patient."

Perry Cohen, Ph.D.,
Project Director

Declaration of Clinical Research Rights and Responsibilities
for People With Parkinson’s

Clinical research is essential to the development of new therapies and treatments for Parkinson’s disease. Yet, due to a number of factors, including a lack of awareness and understanding of the research process, only one percent of people with Parkinson’s participate. This is far below the number needed, delaying many promising trials. Read the entire Declaration!

"Ethical Issues in Clinical Neuroscience Research: A Patient's Perspective"

Written by Parkinson Pipeline Project members
Published in Neurotherapeutic, Vol. 4, No. 3, 2007.
Read the article

To access PD Pipeline database records related to these news items - please click on

Eisai terminates all E2007 phase III clinical trials for Parkinson's. Read press release. (4/11/08)

Neurologix Receives FDA Clearance to Initiate Phase II Gene Therapy Trial in Parkinson's Disease Subjects. Read press release. (3/27/08)

Sponsor receives FDA Not Approvable Letter for Istradefylline (KW-6002). Read press release (3/9/08)

"Common High Blood Pressure Treatment Seems to Reduce Risk of Parkinson’s Disease: What Does It Mean for PD Patients? " Read an Interview of Dr. James Surmeier by the Michael J Fox Foundation. Read press release (2/29/08)

FDA grants Solvay Fast Track designation for its development program for Duodopa (levodopa/carbidopa intestinal gel) for treatment of motor fluctuations associated with advanced Parkinson's disease Read press release (2/18/08)

FDA delays final approval of once-a-day Requip XL (Jan 17, 2008) Read the full article

Phytopharm (UK) was awarded a grant from the The Michael J. Fox Foundation to support the development of Cogane. Taken orally, it is believed Cogane crosses the blood-brain barrier and stimulates the release of GDNF in the brain. (1/22/08) Read the press release

FDA Signals High Bar for Stem Cell Treatments. Read full article and comments in Wall Street Journal Health Blog.

UCB advises US-physicians to down-titrate patients on Neupro(R) in view of out-of-stock situation in the US. UCB initiates recall of Neupro(R) batches, which will lead to an out-of-stock situation in the United States in late April. Patients in the US are advised to contact their healthcare provide) r. Neupro(R) supply is sufficient in other regions. Read press release (3/20/08)
Update on Neupro Recall (4/21/08)

Supreme Court Declines to Hear Case on Access to Experimental Medications for Terminally ill Patients Read the full article (Jan 17, 2008)

When Registering Trials is No Help by Merrill Goozner, from GoozNews blog, March 7 2008
Read article

Gains Come with Risks, Sometimes Personal Costs by Peggy Willocks

Profit Over Common Sense
Andy Grove Speaks to Society for Neuroscience

New data has patient advocates still asking: Why did Amgen halt its GDNF trials?
Given the overwhelmingly positive phase I trial results, and the inconclusive results of the phase II trial, the research should have been continued.

Tell Us What You Think

Your access to and use of the information contained in this web site is subject to this Terms and Conditions of Use Agreement. By accessing and using this web site, you accept this Terms and Conditions of Use Agreement.

The contents of this website and all communications with Parkinson Pipeline Project (PPP) are solely for information purposes and are not intended as medical advice. While we make every effort to assure that the information is accurate and up to date, an error may >occasionally occur. All information and materials are provided AS IS without any warranty of any kind. In no event will the PPP be held liable for any damages arising out of information contained in our website.

If any provision of this Terms and Conditions of Use Agreement is held to be unlawful, void, or unenforceable, then such provision shall be deemed severed without affecting the enforceability of all remaining provisions.